Fasenra is approved for the treatment of severe eosinophilic asthma (SEA), administered with injections every four weeks. The study was funded by AstraZeneca. Fasenra was first approved by the US ...

AZ said Fasenra (benralizumab) has been approved as an add-on maintenance treatment in adults with severe eosinophilic asthma, inadequately controlled on standard inhaled corticosteroid and long ...

Blue Cross Blue Shield company Health Care Service Corporation is limiting access for in-office administration of asthma ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

A revolutionary new asthma attack treatment has been found for the first ... Benralizumab, which is usually know by its brand name Fasenra, was developed by MedImmune for the treatment of Ashtma.

The FDA is to review Sanofi/Regeneron's Dupixent as a treatment for asthma ... Competitors include AZ's Fasenra[/caption] But there is increasing competition in the asthma market, with AstraZeneca ...

AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...

asthma-related deaths, and hospitalization. DCGI approves AstraZeneca's injection 'Fasenra' for treatment of severe eosinophilic asthma Eosinophilic asthma (EA) is a type of asthma that is ...

Juan Celedón and his research team have altered the possibilities of future asthma treatment by uncovering a new way to ...

Key drivers include Breztri Aerosphere (budesonide, formoterol fumarate, and glycopyrrolate) and Fasenra, both of which are positioned for indication expansions into severe asthma and COPD.